Evidence map›Paper›PMID 29777869›Full record

ArticleThe ocular surface2018

Subconjunctival dendrimer-drug therapy for the treatment of dry eye in a rabbit model of induced autoimmune dacryoadenitis.

Hui Lin, Ying Liu, Siva P Kambhampati, Chih-Chien Hsu, Rangaramanujam M Kannan, Samuel C Yiu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The ocular surface, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Recent progress of nanomedicine in managing dry eye disease.Advances in ophthalmology practice and research
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 2 countries.

Hui LinThe Wilmer Eye Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, United States; The Center for Nanomedicine, Johns Hopkins University, Baltimore, MD, United States.
Ying LiuThe Wilmer Eye Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, United States; The Center for Nanomedicine, Johns Hopkins University, Baltimore, MD, United States.
Siva P KambhampatiThe Wilmer Eye Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, United States; The Center for Nanomedicine, Johns Hopkins University, Baltimore, MD, United States.
Chih-Chien HsuThe Wilmer Eye Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, United States; Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.
Rangaramanujam M KannanThe Wilmer Eye Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, United States; The Center for Nanomedicine, Johns Hopkins University, Baltimore, MD, United States. Electronic address: krangar1@jhmi.edu.
Samuel C YiuThe Wilmer Eye Institute, School of Medicine, Johns Hopkins University, Baltimore, MD, United States; The Center for Nanomedicine, Johns Hopkins University, Baltimore, MD, United States. Electronic address: syiu2@jhmi.edu.
Johns Hopkins University · US

Funding

Systemic nanotherapies for ocular inflammation and choroidal neovascularization.R01EY025304 · NEI · JOHNS HOPKINS UNIVERSITY · PI RANGARAMANUJAM, KANNAN · 2015 to 2018
$1.6M
NEI NIH HHS R01 EY025304
6 · The paper itself

Abstract

purposeTo investigate the efficacy of a single subconjunctival injection of dendrimer-dexamethasone conjugate in a rabbit model of induced autoimmune dacryoadenitis (AID).

methodsDendrimer biodistribution after subconjunctival injection in AID animals was evaluated using Cy5-labelled dendrimer (D-Cy5) and confocal microscopy. Diseased animals were treated with free dexamethasone (Free-Dex), dendrimer-dexamethasone (D-Dex), or saline via a single subconjunctival injection. The efficacy was evaluated using various clinical evaluations, such as Schirmer's test, tear breakup time (TBUT), and fluorescein and rose Bengal staining. Histopathology was evaluated by H&E staining and immunostaining. Levels of inflammatory cytokines and aquaporin proteins in the LGs were determined by real-time PCR.

resultsSubconjunctivally administered dendrimers selectively localized in the inflamed LGs, and were taken up by the infiltrating cells. At two weeks post single dose-treatment, the D-Dex group showed improved clinical evaluations. No significant changes were observed in other groups. H&E staining demonstrated less inflammatory cell infiltration and fewer atrophic acini in D-Dex group, compared to those treated with saline or Free-Dex. Immunohistochemistry demonstrated that the intensity of CD-18 (+) and RTLA (+) was weaker in LGs in the D-Dex group than in other treatment groups. Pro-inflammatory gene expression levels of MMP9, IL6, IL8, and TNFα were significantly decreased in the D-Dex group compared to the Free-Dex and saline group.

conclusionsThe dendrimer exhibits pathology-dependent biodistribution in the inflamed LGs. Subconjunctivally administered D-Dex suppressed LG inflammation, leading to partial recovery of LG function with clinical improvement in induced AID. Sjögren's patients may benefit from this targeted nanomedicine approach.

Indexed as

AnimalsAquaporinsBiomarkersCytokinesDacryocystitisDelayed-Action PreparationsDendrimersDexamethasoneDisease Models, AnimalDry Eye SyndromesInjections, IntraocularMaleRabbitsAquaporinsBiomarkersCytokinesDelayed-Action PreparationsDendrimersDexamethasoneAutoimmune dacryoadenitisDendrimerDexamethasoneDry eyeSjögren's syndromeSubconjunctival injection

Identifiers

PMID29777869
PMCPMC7046171
OpenAlexW2804601320

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.